Terms: = Colorectal cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB
4365 results:
1. Pharmacokinetic studies, molecular docking, and molecular dynamics simulations of phytochemicals from Morus alba: a multi receptor approach for potential therapeutic agents in colorectal cancer.
Stany B; Mishra S; Rao KVB
Med Oncol; 2024 May; 41(6):156. PubMed ID: 38750377
[TBL] [Abstract] [Full Text] [Related]
2. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance).
Quintanilha JCF; Sibley AB; Liu Y; Niedzwiecki D; Halabi S; Rogers L; O'Neil B; Kindler H; Kelly W; Venook A; McLeod HL; Ratain MJ; Nixon AB; Innocenti F; Owzar K
BMC Genomics; 2024 May; 25(1):473. PubMed ID: 38745123
[TBL] [Abstract] [Full Text] [Related]
3. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
Wang DS; Ren C; Li SS; Fong WP; Wu XJ; Xiao J; Li BK; Zheng Y; Ding PR; Chen G; Qiu MZ; Wang ZQ; Wang FH; Luo HY; Wang F; Wang XZ; Wang LY; Xie DJ; Chen T; Li LR; Lu ZH; Zhai XH; Liu TS; Yuan Y; Chen JQ; Tan Q; Pan ZZ; Wan DS; Zhang R; Yuan YF; Xu RH; Li YH
PLoS Med; 2024 May; 21(5):e1004389. PubMed ID: 38728364
[TBL] [Abstract] [Full Text] [Related]
4. Cetuximab inhibits colorectal cancer development through inactivating the Wnt/β-catenin pathway and modulating PLCB3 expression.
Zhang X; Zhou W; Wu C; Jiang J; Guo Q; Feng L; Cheng X; Zhang X
Sci Rep; 2024 May; 14(1):10642. PubMed ID: 38724565
[TBL] [Abstract] [Full Text] [Related]
5. CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1α-mediated glycometabolism alteration.
Geng Y; Zheng X; Zhang D; Wei S; Feng J; Wang W; Zhang L; Wu C; Hu W
Biol Direct; 2024 May; 19(1):36. PubMed ID: 38715141
[TBL] [Abstract] [Full Text] [Related]
6. Predictors for temporary stomas non-closure among non-metastatic rectal cancer patients undergoing curative resection: a retrospective analysis.
Hsu CC; Tsai WS; Tsai TY; You JF; Yeh CY; Hsieh PS; Tang R; Huang SH
World J Surg Oncol; 2024 May; 22(1):124. PubMed ID: 38715036
[TBL] [Abstract] [Full Text] [Related]
7. Morphological Changes Induced by TKS4 Deficiency Can Be Reversed by EZH2 Inhibition in colorectal Carcinoma Cells.
Jacksi M; Schad E; Tantos A
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672463
[TBL] [Abstract] [Full Text] [Related]
8. Emerging trends in gastrointestinal cancers: Targeting developmental pathways in carcinogenesis and tumor progression.
Ahmad A; Tiwari RK; Siddiqui S; Chadha M; Shukla R; Srivastava V
Int Rev Cell Mol Biol; 2024; 385():41-99. PubMed ID: 38663962
[TBL] [Abstract] [Full Text] [Related]
9. Genomic landscape of diploid and aneuploid microsatellite stable early onset colorectal cancer.
Zhou Y; Chen X; Chen J; Kendrick CD; Ramanathan RK; Graham RP; Kossick KF; Boardman LA; Barrett MT
Sci Rep; 2024 Apr; 14(1):9368. PubMed ID: 38654044
[TBL] [Abstract] [Full Text] [Related]
10. [Chinese expert consensus on maintenance treatment with anti-egfr monoclonal antibody for
Committee of Colorectal Experts, Chinese Society of Clinical Oncology
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):316-325. PubMed ID: 38644236
[TBL] [Abstract] [Full Text] [Related]
11. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract] [Full Text] [Related]
12. A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells.
Fonseca P; Cui W; Struyf N; Tong L; Chaurasiya A; Casagrande F; Zhao H; Fernando D; Chen X; Tobin NP; Seashore-Ludlow B; Lundqvist A; Hartman J; Göndör A; Östling P; Holmgren L
J Exp Clin Cancer Res; 2024 Apr; 43(1):107. PubMed ID: 38594748
[TBL] [Abstract] [Full Text] [Related]
13. Isthmin-1 promotes growth and progression of colorectal cancer through the interaction with egfr and YBX-1.
Zhou X; Zhang K; Wang C; Teng Y; Yu P; Cai W; Gao W; Li M; Ding Y; Sun P; Chen F; Wang Y; Ma J; Maeshige N; Ma X; Li Q; Liang X; Zhang Y; Su D
Cancer Lett; 2024 May; 590():216868. PubMed ID: 38593920
[TBL] [Abstract] [Full Text] [Related]
14. Anti-egfr Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic colorectal cancer: A Nonrandomized Controlled Trial.
Ciardiello D; Martinelli E; Troiani T; Mauri G; Rossini D; Martini G; Napolitano S; Famiglietti V; Del Tufo S; Masi G; Santini D; Avallone A; Pietrantonio F; Lonardi S; Di Maio M; Zampino MG; Fazio N; Bardelli A; Siena S; Cremolini C; Sartore-Bianchi A; Ciardiello F
JAMA Netw Open; 2024 Apr; 7(4):e245635. PubMed ID: 38592721
[TBL] [Abstract] [Full Text] [Related]
15. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).
Arai H; Tsuda T; Sunakawa Y; Shimokawa M; Akiyoshi K; Tokunaga S; Shoji H; Kunieda K; Kotaka M; Matsumoto T; Nagata Y; Mizukami T; Mizuki F; Danenberg KD; Boku N; Nakajima TE
Cancer Med; 2024 Apr; 13(7):e7107. PubMed ID: 38591098
[TBL] [Abstract] [Full Text] [Related]
16. Indoxyl sulfate contributes to colorectal cancer cell proliferation and increased egfr expression by activating AhR and Akt.
Ichisaka Y; Yano S; Nishimura K; Niwa T; Shimizu H
Biomed Res; 2024; 45(2):57-66. PubMed ID: 38556263
[TBL] [Abstract] [Full Text] [Related]
17. Unveiling Prognostic RNA Biomarkers through a Multi-Cohort Study in colorectal cancer.
Kim Z; Lee J; Yoon YE; Yun JW
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542291
[TBL] [Abstract] [Full Text] [Related]
18. Targeting
Ros J; Vaghi C; Baraibar I; Saoudi González N; Rodríguez-Castells M; García A; Alcaraz A; Salva F; Tabernero J; Elez E
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542278
[TBL] [Abstract] [Full Text] [Related]
19. HER2-Positive Metastatic colorectal cancer.
Robinson HR; Messersmith WA; Lentz RW
Curr Treat Options Oncol; 2024 May; 25(5):585-604. PubMed ID: 38539034
[TBL] [Abstract] [Full Text] [Related]
20. Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.
Zhou YW; Zhao X; Ni L; Cao P; Leng WB; Zhu Q; Gou HF; Zhang J; Li XF; Qiu M
Int Immunopharmacol; 2024 Apr; 131():111887. PubMed ID: 38503018
[TBL] [Abstract] [Full Text] [Related]
[Next]
